Study guide
4.2 Hypersensitivity, Autoimmunity & Immunodeficiency
NBME Comprehensive Basic Science Examination CBSE
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Navigation
1.1 Current Exam Facts & Administration 1.2 Content Blueprint & Physician Tasks 1.3 Scoring, Score Reports & Step 1 Readiness
2 Human Development
2.1 Embryology & Congenital Development Patterns 2.2 Normal Age-Related Findings & Well-Patient Care
3 Blood & Hematologic Disease
3.1 Hematopoiesis, RBC Disorders & Anemias 3.2 Hemostasis, Thrombosis & Coagulopathies 3.3 WBC Disorders, Leukemia & Lymphoma Mechanisms
4 Immune System
4.1 Innate & Adaptive Immunity Mechanisms 4.2 Hypersensitivity, Autoimmunity & Immunodeficiency 4.3 Transplant Immunology & Immune Pharmacology
5 Nervous System Anatomy & Disease
5.1 Neuroanatomy Localization & Pathways 5.2 Stroke, Infection, Demyelination & Trauma 5.3 Seizures, Movement Disorders & Neurodegeneration 5.4 Special Senses: Eye & Ear Mechanisms
6 Behavioral Health
6.1 Psychiatric Disorders & Diagnostic Patterns 6.2 Psychopharmacology Mechanisms 6.3 Neurotransmitters, Learning & Behavioral Science
7 Musculoskeletal System
7.1 Bone Physiology, Fracture Healing & Bone Pathology 7.2 Joint Disease, Rheumatology & Connective Tissue 7.3 Muscle, NMJ & Peripheral Nerve Disorders
8 Skin & Soft Tissue
8.1 Dermatopathology High-Yield Lesions 8.2 Inflammation, Wound Healing & Soft-Tissue Infection
9 Cardiovascular Pathophysiology
9.1 Cardiac Cycle, Hemodynamics & Murmurs 9.2 Ischemic Heart Disease & Cardiomyopathy 9.3 Congenital & Valvular Heart Disease 9.4 Vascular Pathology & Hypertension
10 Cardiovascular Pharmacology
10.1 Antihypertensives, Heart Failure & Antiarrhythmics 10.2 Antiplatelets, Anticoagulants & Lipid Drugs
11 Respiratory System
11.1 Pulmonary Mechanics & Gas Exchange 11.2 Obstructive, Restrictive & Vascular Lung Disease 11.3 Pulmonary Infections, Neoplasms & Respiratory Pharmacology
12 Renal Physiology & Electrolytes
12.1 Nephron Transport & Renal Physiology 12.2 Electrolyte Disorders 12.3 Acid-Base Physiology & Compensation
13 Renal Pathology
13.1 Glomerular Disease Mechanisms 13.2 Tubulointerstitial, Vascular & Stone Disease
14 Gastrointestinal System
14.1 GI Physiology, Motility & Digestion 14.2 Esophagus, Stomach & Intestinal Pathology 14.3 Liver, Biliary Tree & Pancreas 14.4 GI Microbiology, Nutrition & Malabsorption
15 Endocrine System
15.1 Hormone Signaling & Hypothalamic-Pituitary Axes 15.2 Thyroid & Parathyroid Disease 15.3 Adrenal Disorders & Steroid Pharmacology 15.4 Diabetes, Glucose Homeostasis & Metabolic Syndrome
16 Reproductive System
16.1 Male & Female Reproductive Physiology 16.2 Pregnancy, Placenta & Developmental Toxicology 16.3 Reproductive Pathology & Hormone-Related Neoplasia
17 Multisystem Processes & Disorders
17.1 Cell Injury, Inflammation & Repair 17.2 Neoplasia Principles & Tumor Biology 17.3 Infection, Sepsis & Multisystem Microbial Disease 17.4 Genetics, Inborn Errors & Environmental Toxicology
18 Biostatistics & Epidemiology
18.1 Study Design, Bias & Causation 18.2 Diagnostic Test Metrics & Screening 18.3 Epidemiology Measures & Population Health
19 Social Sciences & Communication
19.1 Ethics Principles & Decision-Making Capacity 19.2 Communication Skills & Difficult Conversations 19.3 Professionalism, Systems & Practice-Based Learning
20 Integrated Disciplines Capstone
20.1 High-Yield Microbiology Anchors Across Systems 20.2 High-Yield Biochemistry & Molecular Mechanisms 20.3 Integrated Pharmacology Strategy & Exam-Day Execution
4.2 Hypersensitivity, Autoimmunity & Immunodeficiency
Key Takeaways Explain This Topic AI
Hypersensitivity types: I (IgE–mast cell), II (IgG/IgM against cell/matrix), III (immune-complex), IV (T-cell delayed/cytotoxic).
Autoimmunity reflects failed central or peripheral tolerance; disease vignettes map to autoantibody or T-cell targets (SLE, RA, myasthenia, Graves, Hashimoto, T1DM, Goodpasture).
B-cell defects → recurrent pyogenic sinopulmonary infections and low Igs; T-cell/SCID → viral, fungal, opportunistic pathogens and vaccine risks.
Phagocyte defects: CGD (NADPH oxidase, catalase-positive organisms), Chediak-Higashi (LYST, giant granules), LAD (integrin/selectin adhesion failure).
Complement patterns: C1-INH deficiency → hereditary angioedema; C5–C9 → Neisseria; early classical defects → immune-complex disease risk.
Last updated: August 2026
Hypersensitivity: Same Tools, Wrong Target or Magnitude
Hypersensitivity reactions are immune effector mechanisms that damage host tissues. Gell and Coombs types I–IV remain the CBSE framework; each type is defined by mechanism , not by organ alone.
Type Mechanism Timing Classic examples
I IgE on mast cells/basophils → allergen cross-links → histamine, tryptase, leukotrienes, prostaglandins Immediate (minutes); late phase hours Anaphylaxis, allergic rhinitis/asthma, food allergy, atopic dermatitis
II IgG/IgM bind cell-surface or matrix antigen → complement, phagocytosis, ADCC, or receptor modulation Hours Autoimmune hemolysis, Goodpasture, rheumatic fever (molecular mimicry), myasthenia (blocking), Graves (stimulating)
III Soluble immune complexes deposit in vessels/tissues → complement and neutrophil damage Hours to days Serum sickness, Arthus reaction, SLE nephritis, post-strep GN patterns
IV CD4-mediated inflammation and/or CD8 cytotoxicity; no antibody required Delayed (48–72 h for classic DTH) Contact dermatitis, tuberculin skin test, Type 1 diabetes islet killing, acute cellular transplant rejection
Type I detail
Sensitization produces allergen-specific IgE that binds high-affinity FcεRI on mast cells. Re-exposure cross-links IgE → intracellular calcium → degranulation (histamine → vasodilation, permeability, bronchospasm) and de novo lipid mediators. Systemic distribution causes anaphylaxis (airway edema, hypotension). Epinephrine is first-line clinically because it reverses mast-cell mediators’ physiologic effects; mechanism questions focus on IgE–FcεRI–mast cell, not drug lists alone.
Type II vs III—bound vs soluble
Type II targets antigen fixed on cells or basement membranes (e.g., anti-GBM in Goodpasture attacking type IV collagen in lung and glomerulus). Type III forms lattices of soluble antigen and antibody that deposit in vessels, joints, and glomeruli, activating complement and recruiting neutrophils. Low-grade chronic complex deposition is a major driver of SLE tissue injury.
Type IV
Haptenized skin proteins presented to memory CD4 cells cause contact dermatitis (nickel, poison ivy urushiol). CD8 cells kill virus-infected or allogeneic cells. Granulomatous inflammation (TB, some fungal disease) is a chronic Type IV pattern with macrophage activation under IFN-γ.
Tolerance and Autoimmunity
Central tolerance deletes or edits strongly self-reactive clones: thymic negative selection of T cells (AIRE-dependent tissue antigen expression in medulla) and bone-marrow editing/deletion of B cells. Peripheral tolerance restrains escapees via anergy (signal 1 without costimulation), Tregs (FoxP3, CTLA-4, IL-10, TGF-β), immune privilege, and activation-induced cell death. Autoimmunity arises when these checkpoints fail in a genetically susceptible host (HLA associations) after environmental triggers (infection, smoking, drugs).
Autoimmune vignette mechanisms
Disease Dominant mechanism (high-yield)
SLE Loss of tolerance to nuclear antigens; immune complexes (Type III) → multi-organ disease; anti-dsDNA ~ nephritis; anti-Sm highly specific
Rheumatoid arthritis Chronic synovitis with citrullinated protein immunity (anti-CCP), RF (IgM anti-IgG), Th1/Th17 and cytokine-driven pannus (TNF, IL-6)
Sjögren Lymphocytic destruction of exocrine glands → dry eyes/mouth; anti-SSA/Ro, anti-SSB/La; risk of lymphoma
Myasthenia gravis Type II antibodies to AChR (or MuSK) → receptor internalization/blockade → fatigable weakness
Graves disease Type II stimulating antibodies to TSH receptor → hyperthyroidism
Hashimoto thyroiditis T-cell–mediated thyroid destruction plus autoantibodies (anti-TPO, anti-Tg) → hypothyroidism
Type 1 diabetes mellitus CD8-mediated β-cell killing; autoantibodies (anti-GAD, IA-2, insulin) as markers
Goodpasture Anti-GBM IgG against type IV collagen (α3 chain) → linear IF in glomeruli/alveoli; pulmonary-renal syndrome
Distinguish receptor-modulating Type II (Graves stimulate, myasthenia block/degrade) from cytotoxic Type II (hemolysis, Goodpasture complement/ADCC). HLA links (e.g., HLA-DR3/DR4 with T1DM and other autoimmunity) illustrate genetic risk without being sole causes.
Primary Immunodeficiency: Cluster by Arm
Approach PIDs by which limb fails and which pathogens dominate , then match the named syndrome.
B-cell / antibody defects
Recurrent sinopulmonary pyogenic bacteria (encapsulated organisms), enteroviral risk with agammaglobulinemia, and poor vaccine antibody responses.
Disorder Defect Clinical pearl
X-linked (Bruton) agammaglobulinemia BTK → pre-B failure; few B cells, all Igs low Boys after maternal IgG wanes; no tonsils/germinal centers
Selective IgA deficiency Most common; IgA low, other Igs usually OK Mucosal infections, allergy/autoimmunity; anaphylaxis risk to IgA-containing products if anti-IgA present
Common variable immunodeficiency (CVID) Heterogeneous B-cell differentiation/T help defects Later onset hypogammaglobulinemia, autoimmunity, lymphoma risk
T-cell and combined defects
Viral, fungal, Pneumocystis , and live-vaccine dangers; poor delayed-type hypersensitivity.
Disorder Defect Clinical pearl
SCID Multiple genes (IL2RG, ADA, RAG, etc.) → absent T (±B/NK) function Failure to thrive, thrush, severe viral/fungal disease; “bubble” phenotype; emergency HSCT
DiGeorge (22q11) Thymic hypoplasia (T-cell), hypocalcemia, cardiac defects 3rd/4th pouch development; variable T-cell deficit
Hyper-IgM (CD40L deficiency) Failed class switch and germinal centers High/normal IgM, low IgG/A/E; opportunistic infections including Pneumocystis
Phagocyte defects
Disorder Defect Organisms / clues
Chronic granulomatous disease (CGD) NADPH oxidase (often CYBB X-linked) → no oxidative burst Catalase-positive: Staph , Aspergillus , Burkholderia , Serratia ; nitroblue tetrazolium/DHR abnormal; granulomas
Chediak-Higashi LYST trafficking → giant granules Partial albinism, recurrent pyogenic infection, neurologic issues, hemophagocytic risk
Leukocyte adhesion deficiency (LAD) Integrin (CD18/LFA-1) or selectin ligand defects High blood neutrophils, no pus at infection sites, delayed umbilical cord separation (LAD-I classic)
Complement defects
- Defect Pattern
- C1-INH deficiency Hereditary angioedema: bradykinin-mediated swelling (not histamine/IgE); low C4; airway risk
- Early classical (C1, C2, C4) SLE-like immune-complex disease; impaired clearance of apoptotic debris/complexes
- C3 deficiency Severe pyogenic infections; immune-complex disease
- C5–C9 (MAC) Recurrent Neisseria
- Alternative pathway / factor defects Pyogenic infections; some with meningococcal risk
- Putting Vignettes Together
A CBSE stem might describe a boy with abscesses from Aspergillus and a negative oxidative burst → CGD, not SCID. Another shows linear IgG along GBM with lung hemorrhage → Type II anti-GBM, not Type III granular deposits of SLE. A teenager with recurrent Neisseria and low CH50 focused on terminal components → MAC deficiency. Anaphylaxis after peanut with elevated tryptase → Type I. Contact dermatitis 2 days after nickel → Type IV. Reasoning always starts from mechanism → effector → clinical pattern , not from memorizing orphan disease names alone.
Tolerance failure vignettes often add family HLA risk or a trigger (drug-induced lupus with anti-histone; molecular mimicry in rheumatic fever Type II against cardiac myosin-like epitopes). Secondary immunodeficiencies (HIV CD4 loss, iatrogenic immunosuppression, protein-losing states) can mimic PID patterns and should be considered when onset is late or exposure history fits—but primary named syndromes remain high-yield for classic age-of-onset and organism clusters.